Provided by Tiger Trade Technology Pte. Ltd.

BridgeBio Pharma, Inc.

75.78
-0.8200-1.07%
Volume:480.42K
Turnover:36.30M
Market Cap:14.84B
PE:-21.24
High:76.77
Open:76.20
Low:75.03
Close:76.60
52wk High:93.42
52wk Low:48.78
Shares:195.81M
Float Shares:167.00M
Volume Ratio:0.71
T/O Rate:0.29%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.5686
EPS(LYR):-3.7850
ROE:-1789.67%
ROA:-26.00%
PB:-5.90
PE(LYR):-20.02

Loading ...

Bridgebio Pharma - Sixth Street Funded $800 Mln; Healthcare Royalty Funded $133.9 Mln at Close

THOMSON REUTERS
·
Jul 01

Market Chatter: KKR, Sixth Street to Invest $1 Billion in BridgeBio Preferred Equity

MT Newswires Live
·
Jul 01

Sixth Street, KKR Provide Bridgebio $1 Billion Preferred Equity- Bloomberg News

Reuters
·
Jul 01

Why BridgeBio Pharma (BBIO) Is Up 8.5% After NEJM-Published Infigratinib Phase 3 Achondroplasia Data

Simply Wall St.
·
Jul 01

Sector Update: Healthcare

MT Newswires Live
·
Jun 29

BridgeBio Pharma Meets Primary Endpoint For Achondroplasia Drug in Phase 3 Trial

MT Newswires Live
·
Jun 29

BridgeBio announces PROPEL 3 trial met primary endpoint

TIPRANKS
·
Jun 29

Bridgebio Says Phase 3 Propel 3 Trial Shows Oral Infigratinib Boosts Growth in Children with Achondroplasia

Reuters
·
Jun 29

Bridgebio Announces Publication in the New England Journal of Medicine of Phase 3 Propel 3 Trial of Oral Infigratinib in Children Living with Achondroplasia

THOMSON REUTERS
·
Jun 29

Bridgebio Shareholders Approved 2 Million-share Increase Under 2021 Equity Plan at Annual Meeting

Reuters
·
Jun 26

Bridgebio Director Hannah Valantine Disposes of Common Shares Worth $341,571.72

Reuters
·
Jun 25

BRIEF-Bridgebio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
Jun 24

BridgeBio Pharma grants 66,810 restricted stock units to 30 new employees under inducement plan

Reuters
·
Jun 24

BridgeBio Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Jun 24

BridgeBio Oncology Therapeutics shareholders elect Lebowitz, McCormick to board

Reuters
·
Jun 23

Movement Alert|BridgeBio Pharma Rises 5.04% in Regular Trading, Trading at $69.625

Market Focus
·
Jun 23

BridgeBio to present Phase 3 PROPEL 3 trial results for oral infigratinib in children with achondroplasia at ICCBH 2026

Reuters
·
Jun 22

BridgeBio director Jennifer E. Cook disposes of common shares worth $6,011,959.36

Reuters
·
Jun 18

Analysts Offer Insights on Healthcare Companies: IQVIA Holdings (IQV), BridgeBio Pharma (BBIO) and Guardant Health (GH)

TIPRANKS
·
Jun 17

BridgeBio Pharma Inc : Mizuho Cuts Target Price to $96 From $106

THOMSON REUTERS
·
Jun 16